Overview

Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia

Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or other adverse events. It is also aimed at indicating effectiveness as compared with oral Finasteride 1mg. In this non-blinded study, each patient will choose his preferred arm (oral finasteride or FOL100 location). During the study, safety and efficacy will be measured as well as usability.
Phase:
Phase 1
Details
Lead Sponsor:
Follicle Pharma Ltd
Treatments:
Finasteride